Dergiler / Experimed / 2022 / Cilt: 12 - Sayı: 3

Cytotoxic and Cytostatic Effects of Targeting mTOR and Hedgehog Pathways in Acute Myeloid Leukemia

Sayfa
202–208
Yayın Tarihi
2022-12-31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It also suggest further studies be performed to reveal the mechanism of action.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Acute myeloid leukemia (AML) is a highly aggressive heterogeneous hematopoietic malignancy characterized by a rapid and abnormal proliferation of immature myeloid leukemia cells in the bone marrow and peripheral blood.
📊
Temel Bulgular & Veri:This study aimed to investigate cell viability and the cell cycle in AML cells by targeting the Hedgehog and mTOR signaling pathways with rapamycin and GANT61.Materials and Method: The antiproliferative effect of rapamycin and GANT61 was assessed by the MTT cell viability assay in two AML cell lines: CMK and MOLM-13.
💡
Sonuç & Katkı:It also suggest further studies be performed to reveal the mechanism of action.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Hedgehog · mTOR · Leukemia

Abstract

Objectives: Acute myeloid leukemia (AML) is a highly aggressive heterogeneous hematopoietic malignancy characterized by a rapid and abnormal proliferation of immature myeloid leukemia cells in the bone marrow and peripheral blood. Aberrant alterations in signal transduction pathways are strongly associated with the progression of AML. This study aimed to investigate cell viability and the cell cycle in AML cells by targeting the Hedgehog and mTOR signaling pathways with rapamycin and GANT61.Materials and Method: The antiproliferative effect of rapamycin and GANT61 was assessed by the MTT cell viability assay in two AML cell lines: CMK and MOLM-13. The effect of the inhibitors on cell-cycle distribution was determined using propidium iodide staining and measured with flow cytometry.Results: Rapamycin, an mTOR inhibitor, and GANT61, a Gli-1 inhibitor, decreased the cell proliferation of CMK and MOLM-13 cells. The IC20 values, which is the drug concentration that inhibits cell growth by 20%, were combined and administered to the cells. The results show the drugs to have a combinatorial inhibitory effect on CMK cells but not on MOLM-13 cells. In addition, the combination of drugs arrested the cells during the G0/G1 phase.Conclusion: This study suggests a novel combination therapy approach for AML via mTOR and Hedgehog signaling pathway inhibition using rapamycin and GANT61, respectively. It also suggest further studies be performed to reveal the mechanism of action.

🔖

Bu Makaleye Atıf Yap

ÇİÇEK, E., KÜÇÜKTAŞ, F. M., YENİGÜL, M., AKCOK, E. G. (2022). Cytotoxic and Cytostatic Effects of Targeting mTOR and Hedgehog Pathways in Acute Myeloid Leukemia. Experimed, Cilt: 12 - Sayı: 3, 202–208. https://ajindex.com/articles/878275

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Darici S, Alkhaldi H, Horne G, J0rgensen HG, Marmiroli S, Huang X. Targeting PI3K/Akt/mTOR in AML: Rationale and clinical evidence. J Clin Med 2020; 9(9): 2934. [CrossRef] google scholar 2. Nepstad I, Hatfield KJ, Gronnings^ter IS, Reikvam H. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci 2020; 21(8): 2907. [CrossRef] google scholar 3. Saultz JN, Garzon R. Acute myeloid leukemia: A concise review. J Clin Med 2016; 5(3): 33. [CrossRef] google scholar 4. Scholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008; 35(4): 336-45. [CrossRef] google scholar 5. Terao T, Minami Y. Targeting Hedgehog (Hh) Pathway for the acute myeloid leukemia treatment. Cells 2019; 8(4): 312. [CrossRef] google scholar 6. Niyaz M, Khan MS, Mudassar S. Hedgehog signaling: An achilles' heel in cancer. Transl Oncol 2019; 12(10): 1334-44. [CrossRef] google scholar 7. Sari IN, Phi LTH, Jun,N, Wijaya YT, Lee S, Kwon HY. Hedgehog signaling in cancer: A prospective therapeutic target for eradicating cancer stem cells. Cells 2018; 7(11): 208. [CrossRef] google scholar 8. Shallis RM, Bewersdorf JP, Boddu PC, Zeidan AM. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert Rev Anticancer Ther 2019; 19: 717-29. [CrossRef] google scholar 9. Long B, Wang LX, Zheng FM, Lai SP, Xu DR, Hu Y, et al. Targeting GLI1 suppresses cell growth and enhances chemosensitivity in CD34+ enriched acute myeloid leukemia progenitor cells. Cell Physiol Biochem 2016; 38(4): 1288-302. [CrossRef] google scholar 10. Ruch JM, Kim EJ. Hedgehog signaling pathway and cancer therapeutics: Progress to date. Drugs. 2013; 73, 613-23. [CrossRef] google scholar 11. Harada K, Ohashi R, Naito K, Kanki K. Hedgehog signal inhibitor GANT61 inhibits the malignant behavior of undifferentiated hepatocellular carcinoma cells by targeting non-canonical GLI signaling. Int J Mol Sci 2020; 21(9): 3126. [CrossRef] google scholar 12. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 2017; 168(6): 960-76. [CrossRef] google scholar 13. Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell Biosci 2020; 10(1): 31. [CrossRef] google scholar 14. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010; 95(5):